patent

Pharmaceutical globalization: Where are drugs invented?

October 18, 2011

I’m back from the Filling the Pipeline conference in Boston, where I presented a talk on pharmaceutical globalization. Maintaining control of pharmaceutical drug innovation is key for national security, public health, and economic development. We know that much of late-stage development has gone overseas, but the question remains: Where are drugs invented? Using the DrugPatentWatch [...]

Read the full article →

Globalization of pharmaceutical innovation

March 31, 2011

Here’s a copy of the talk I gave at the American Chemical Society meeting, on using patent information to track globalization: Using patent information to track globalization Check out it. I think the findings will surprise you!

Read the full article →

Using patent information to track globalization

March 23, 2011

I will be giving a talk on “Using patent information to track globalization” at the ACS conference in Anaheim next week. The talk is part of the ACS Division of Chemistry and Law session on What Can Patent Information Do For Scientists, and is based on analysis of data from DrugPatentWatch. I look forward to [...]

Read the full article →

Featured in Fortune article on Drug Patent Challenges

March 11, 2011

Fortune magazine recently published an article on the growing trend of generic companies challenging pharmaceutical drug patents. I enjoyed working with the writer to help layout the industry landscape, and share my knowledge of drug patents and trends from DrugPatentWatch.com. It’s a good read, and it does an excellent job of laying out the legal, [...]

Read the full article →

Globalization in the pharmaceutical industry: Where are drugs invented?

November 1, 2010

I’ve just had a paper published in Nature Reviews Drug Discovery, using data from DrugPatentWatch to profile the locations of drug invention for the past decade. The location of drug development is important for two reasons. Firstly, it is important to track the global spread of innovation. Much late stage drug development (e.g. clinical trials) [...]

Read the full article →

New reports from DrugPatentWatch

September 10, 2010

New Reports Based on Data-Mining the DrugPatentWatch database Please contact us with any special data requirements beyond the existing report catalog Orphan Drug Report The Orphan Drug Report profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity The Report includes: The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug Details on each [...]

Read the full article →

Drug Patent Challenge Report

September 3, 2010

I’ve posted a new Drug Patent Challenge Report at thinkPharm.com. This new report complements the Drug Patent Inventor Report and Orphan Drug Report and profiles the companies that successfully challenged pharmaceutical drug patents. The Drug Patent Challenge Report includes: A list of the companies with the most successful patent challenges A list of all the [...]

Read the full article →

Drug inventor report profiles individuals, US states, and countries leading pharmaceutical innovation

August 16, 2010

A new report from DrugPatentWatch.com profiles the leading researchers, US states, and countries responsible for drugs approved over the past ten years. The report features: Top Inventors Which inventors were granted the most patents? Patents per Inventor The patents awarded to each inventor Approved Drugs per Inventor The approved drugs protected by each inventor’s patents [...]

Read the full article →

India, Intellectual Property and Biotechnology Industry

December 3, 2009

This is a guest post from BiotechBlog reader Viren Konde. Do you have a response to Viren’s post? If so, you may respond in the comments section below. The recent editorial on “Intellectual property and biotechnology innovation: To protect or not protect” by Dr Yali Friedman, Managing Editor of the Journal of Commercial Biotechnology was [...]

Read the full article →

Biologic data exclusivity: The arguments for and against it

October 26, 2009

With the issue of data exclusivity for novel biologics re-emerging in the news, I’d like to present two arguments that will be published in the upcoming issue of the Journal of Commercial Biotechnology: Why data exclusivity is the new patent protection Peter J Pitts, Center for medicine in the public interest Follow-on biologic drug competition [...]

Read the full article →

← Previous Entries